Kymera Therapeutics (KYMR) Income from Continuing Operations (2019 - 2026)
Kymera Therapeutics (KYMR) reported Income from Continuing Operations of 84215000.0 for Q1 2026, down 13.04% year-over-year from 96847055.0 in Q1 2025, and up 14.05% quarter-over-quarter from 97986000.0 in Q4 2025.
Kymera Therapeutics (KYMR) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Income from Continuing Operations data on file, last reported at 84215000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 84215000.0, down 13.04% year-over-year; the trailing twelve-month figure through Mar 2026 was 359485000.0 (down 29.09% YoY), and the FY2025 annual result was 349769000.0, down 33.56% from the prior year.
- Income from Continuing Operations climbed to 84215000.0 in Q1 2026 per KYMR's latest filing, from 97986000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 19364000.0 in Q4 2023 and troughed at 97986000.0 in Q4 2025.
- A 5-year average of 60177941.18 and a median of 57550000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 49.95% in 2023, then tumbled 317.34% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 38689000.0 in 2022, then jumped by 49.95% to 19364000.0 in 2023, then sank by 317.34% to 80814000.0 in 2024, then decreased by 21.25% to 97986000.0 in 2025, then gained by 14.05% to 84215000.0 in 2026.
- Business Quant data shows KYMR's Income from Continuing Operations at 84215000.0 in Q1 2026, 97986000.0 in Q4 2025, and 92619000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -84.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.22 Mn |
| Dec 31, 2025 | -97.99 Mn |
| Sep 30, 2025 | -92.62 Mn |
| Jun 30, 2025 | -84.67 Mn |
| Mar 31, 2025 | -74.50 Mn |
| Dec 31, 2024 | -80.81 Mn |
| Sep 30, 2024 | -72.18 Mn |
| Jun 30, 2024 | -50.99 Mn |
| Mar 31, 2024 | -57.90 Mn |
| Dec 31, 2023 | -19.36 Mn |
| Sep 30, 2023 | -57.55 Mn |
| Jun 30, 2023 | -43.43 Mn |
| Mar 31, 2023 | -45.38 Mn |
| Dec 31, 2022 | -38.69 Mn |
| Sep 30, 2022 | -44.92 Mn |
| Jun 30, 2022 | -40.85 Mn |
| Mar 31, 2022 | -36.97 Mn |
| Dec 31, 2021 | -34.05 Mn |
| Sep 30, 2021 | -28.71 Mn |
| Jun 30, 2021 | -24.76 Mn |